News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Texas Stem Cell Law Opens Door for Controversial Treatments
Anna Azvolinsky | Mar 27, 2018
looks at one such Houston-based purveyor that has been treating patients abroad for years with mesenchymal stem cells.
Opinion: No, FDA Didn’t Really Approve 23andMe’s
Cecile Janssens | Mar 19, 2018
Rather, the breast cancer mutation screen was classified as a type of medical device with obligations for the company to reduce risks to customers.
Recipients of Experimental Herpes Vaccine File Lawsuit
Catherine Offord | Mar 15, 2018
The suit claims that Rational Vaccines, the company of recently deceased researcher William Halford, violated US and international laws when it carried out the procedure.
First Direct-to-Consumer BRCA Test Authorized by FDA
Kerry Grens | Mar 6, 2018
The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.
FDA Report on BPA’s Health Effects Raises Concerns
Ashley Yeager | Feb 28, 2018
The pre-peer review assessment finds the compound has “minimal effects,” but endocrinologists and others say key data have yet to come out.
CDC, FDA Warn Against Kratom Use
Jim Daley | Feb 26, 2018
The herbal supplement, deemed an opioid by the FDA, was recently linked to a
outbreak in 20 states.
New Automated Tool Monitors Clinical Trial Reporting
Diana Kwon | Feb 22, 2018
The watchdog website FDAAA TrialsTracker names and shames human studies that breach the FDA’s requirements for reporting results.
CDC: Flu Vaccine 36 Percent Effective So Far
Catherine Offord | Feb 16, 2018
The vaccine shows better-than-expected effectiveness against the most common and most virulent strain of influenza in children under 9 years old.
First Blood Test for Concussion Approved by FDA
Kerry Grens | Feb 16, 2018
The diagnostic measures two proteins indicative of brain injury.
Proposed Federal Budget Slashes Funds to EPA, CDC
Diana Kwon | Feb 13, 2018
Funds for the NIH and NSF would stay flat, while some agencies, including the FDA and NASA, would see increases.